Current Role and Responsibilities
Cem Shaquer holds the position of Vice President of Research & Development (R&D) for Radiation Oncology Solutions at Varian Medical Systems, a part of Siemens Healthineers. This role commenced approximately 10 months ago, indicating a recent leadership transition within the organization. His portfolio encompasses overseeing R&D initiatives specifically geared toward advancing radiation oncology technologies and solutions. Given Varian’s strategic focus on innovation in cancer treatment, Cem Shaquer’s leadership is aligned with driving product development and clinical technology enhancements that improve patient outcomes in oncology.
Professional Background and Expertise
Cem Shaquer is based in the San Francisco Bay Area and has a professional background that includes extensive experience in medical device development, leadership, strategy formulation, and execution within the healthcare technology sector. His expertise spans the execution of complex healthcare R&D projects, notably in the cardiac and oncology spaces.
Educationally, he is affiliated with Orta Doğu Teknik Üniversitesi (Middle East Technical University). While detailed biographical data and specific career achievements are limited, his progression to a VP-level R&D role in a specialized segment like radiation oncology indicates substantial prior involvement in product innovation and quality systems within Varian Medical Systems.
Company Context – Varian Medical Systems
Varian Medical Systems is a global leader in oncology treatment technologies, including advanced radiation therapy devices that serve university research hospitals, community hospitals, private and governmental healthcare institutions worldwide. The company remains committed to innovation, evidenced by its role in a 10-year transformational oncology collaboration with Ballad Health to extend advanced treatment capabilities to rural communities (announced in September 2024). Varian is also renowned for its leadership in integrated cancer care solutions, continuously enhancing therapy personalization through clinical trial support and imaging advancements.
Varian has sustained industry recognition, being listed among the world’s 100 most sustainable corporations, highlighting its commitment to sustainable and responsible business operations.
Industry and Innovation Focus
Under Cem Shaquer’s VP leadership in R&D, Varian’s Radiation Oncology Solutions emphasize integration of novel technologies that address tumor motion management, image guidance, and personalized cancer therapy. The company actively showcases developments in respiratory gating, dual-energy imaging, and other precision oncology modalities.
The integration of Varian into Siemens Healthineers further strengthens its innovation ecosystem, combining portfolio expertise and expanding its reach in cancer care. Posts from Cem Shaquer emphasize a forward-looking R&D culture focused on new beginnings, innovation, and advancing radiation oncology.
Relevant Insights for Strategic Engagement
- Cem Shaquer’s senior leadership role centers on the innovation pipeline and development of radiation oncology solutions, suggesting direct influence on technology evaluation and acquisition decisions related to oncology R&D tools and platforms.
- His position reflects responsibility for scaling cutting-edge medical devices that blend software, hardware, and clinical applications in a regulated environment, requiring compliance, quality assurance, and clinical validation.
- Varian’s recent strategic collaborations and Siemens Healthineers affiliation align with expanding solutions targeted at underserved markets, including rural healthcare providers.
Familiarity with R&D challenges in regulated medical environments, particularly oncology device development and clinical trial enablement, would resonate given Cem’s current remit.
This profile integrates all pertinent, up-to-date information available on Cem Shaquer as a key executive at Varian Medical Systems, with a focus on actionable insights and contextual relevance within medical device innovation and oncology treatment evolution.
